Literature DB >> 15527703

Primary versus secondary antiphospholipid syndrome: is this lupus or not?

Jennifer M Grossman1.   

Abstract

Antiphospholipid syndrome is a hypercoaguable state characterized by recurrent venous and/or arterial thrombosis and/or pregnancy complications of fetal loss, pre-eclampsia, or eclampsia in the presence of antiphospholipid antibodies. It was first described in the setting of systemic lupus erythematosus and subsequently recognized to also exist as an independent condition and in conjunction with a variety of other autoimmune, infectious, and malignant illnesses. These diseases have been called primary antiphospholipid syndrome and secondary antiphospholipid syndrome. However, the two conditions can have significant overlapping features. This paper reviews the similarities and the differences between the two conditions.

Entities:  

Mesh:

Year:  2004        PMID: 15527703     DOI: 10.1007/s11926-004-0023-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  39 in total

1.  Acute interstitial pneumonia associated with antiphospholipid syndrome in a patient with systemic sclerosis.

Authors:  M Minatani; J Takasaki; H Iwata; M Kinoshita; S Aotsuka; M Sumiya
Journal:  Clin Exp Rheumatol       Date:  2000 Nov-Dec       Impact factor: 4.473

2.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

Authors:  Mark A Crowther; Jeff S Ginsberg; Jim Julian; Judah Denburg; Jack Hirsh; James Douketis; Carl Laskin; Paul Fortin; David Anderson; Clive Kearon; Ann Clarke; William Geerts; Melissa Forgie; David Green; Lorrie Costantini; Wendy Yacura; Sarah Wilson; Michael Gent; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

3.  Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 74 patients.

Authors:  A L Fauchais; M Lambert; D Launay; U Michon-Pasturel; V Queyrel; N Nguyen; M Hebbar; E Hachulla; B Devulder; P Y Hatron
Journal:  Lupus       Date:  2004       Impact factor: 2.911

4.  Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients.

Authors:  G Vargas-Alarcon; J Granados; C Bekker; J Alcocer-Varela; D Alarcón-Segovia
Journal:  Arthritis Rheum       Date:  1995-09

5.  Exclusion criteria for primary antiphospholipid syndrome.

Authors:  J C Piette; B Wechsler; C Frances; T Papo; P Godeau
Journal:  J Rheumatol       Date:  1993-10       Impact factor: 4.666

6.  Primary antiphospholipid syndrome evolving into systemic lupus erythematosus.

Authors:  F Mujic; M J Cuadrado; M Lloyd; M A Khamashta; G Page; G R Hughes
Journal:  J Rheumatol       Date:  1995-08       Impact factor: 4.666

7.  Catastrophic antiphospholipid syndrome in a patient with Behçet's disease.

Authors:  Giuseppe Famularo; Salvatore Antonelli; Annalisa Barracchini; Maurizio Menichelli; Giulio Cesare Nicotra; Giovanni Minisola
Journal:  Scand J Rheumatol       Date:  2002       Impact factor: 3.641

8.  Is HLA class II susceptibility to primary antiphospholipid syndrome different from susceptibility to secondary antiphospholipid syndrome?

Authors:  M V C Freitas; L M da Silva; N H S Deghaide; E A Donadi; P Louzada-Júnior
Journal:  Lupus       Date:  2004       Impact factor: 2.911

9.  High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.

Authors:  Guillermo Ruiz-Irastorza; Maria-Victoria Egurbide; Jon Ugalde; Ciriaco Aguirre
Journal:  Arch Intern Med       Date:  2004-01-12

10.  Anticardiolipin antibodies in a patient with Crohn's disease and thrombosis.

Authors:  J L Vianna; D P D'Cruz; M A Khamashta; R A Asherson; G R Hughes
Journal:  Clin Exp Rheumatol       Date:  1992 Mar-Apr       Impact factor: 4.473

View more
  2 in total

1.  Distinct antibody profile: a clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus?

Authors:  Paula Vieira Freire; Elisa Watanabe; Nelita Rocha dos Santos; Cleonice Bueno; Eloísa Bonfá; Jozélio Freire de Carvalho
Journal:  Clin Rheumatol       Date:  2014-01-14       Impact factor: 2.980

2.  Introducing polyautoimmunity: secondary autoimmune diseases no longer exist.

Authors:  Adriana Rojas-Villarraga; Jenny Amaya-Amaya; Alberto Rodriguez-Rodriguez; Rubén D Mantilla; Juan-Manuel Anaya
Journal:  Autoimmune Dis       Date:  2012-02-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.